Table V.
Association between PCDH-γ-A12, SLC19A1, CREB and CYLD methylation in CRC serum and clinicopathological features.
| PCDH-γ-A12 | SLC19A1 | CREB | CYLD | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | Subgroup | Patient, n | M | U | P-value | M | U | P-value | M | U | P-value | M | U | P-value |
| Gender | Male | 28 | 25 | 3 | 0.306 | 21 | 7 | 0.690 | 7 | 21 | 1 | 4 | 24 | 1.000 |
| Female | 14 | 10 | 4 | 12 | 2 | 4 | 10 | 2 | 12 | |||||
| Age (years) | ≤60 | 16 | 14 | 2 | 0.887 | 10 | 6 | 0.109 | 4 | 12 | 1 | 3 | 13 | 0.846 |
| >60 | 26 | 21 | 5 | 23 | 3 | 7 | 19 | 3 | 23 | |||||
| TNM stage | 1, 2 | 21 | 18 | 3 | 1.000 | 17 | 4 | 1.000 | 6 | 15 | 0.547 | 2 | 19 | 0.659 |
| 3, 4 | 21 | 17 | 4 | 16 | 5 | 5 | 16 | 4 | 17 | |||||
| Lymph metastasis | Yes | 21 | 21 | 0 | 0.013 | 20 | 1 | 0.024 | 7 | 14 | 0.292 | 4 | 17 | 0.756 |
| No | 21 | 14 | 7 | 13 | 8 | 4 | 17 | 2 | 19 | |||||
| Distant metastasis | Yes | 8 | 7 | 1 | 1.000 | 8 | 0 | 0.245 | 4 | 4 | 0.209 | 3 | 5 | 0.128 |
| No | 34 | 28 | 6 | 25 | 9 | 7 | 27 | 3 | 31 | |||||
| CEA | ≥5.0 ng/ml | 15 | 12 | 3 | 1.000 | 10 | 5 | 0.313 | 3 | 12 | 0.754 | 3 | 12 | 0.742 |
| <5.0 ng/ml | 27 | 23 | 4 | 23 | 4 | 8 | 19 | 3 | 24 | |||||
| CA19-9 | ≥37 U/ml | 9 | 7 | 2 | 1.000 | 6 | 3 | 0.600 | 3 | 6 | 0.903 | 2 | 7 | 0.818 |
| <37 U/ml | 33 | 28 | 5 | 27 | 6 | 8 | 25 | 4 | 29 | |||||
| Tumor location | Colon | 26 | 21 | 5 | 0.887 | 23 | 3 | 0.109 | 8 | 18 | 0.618 | 3 | 23 | 0.846 |
| Rectum | 16 | 14 | 2 | 10 | 6 | 3 | 13 | 3 | 13 | |||||
| Differentiation | Poor | 10 | 9 | 1 | 0.871 | 9 | 1 | 0.570 | 4 | 6 | 0.468 | 2 | 8 | 0.941 |
| Moderate | 32 | 26 | 6 | 24 | 8 | 7 | 25 | 4 | 28 | |||||
| Good | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Tumor size | <5 cm | 28 | 23 | 5 | 1.000 | 22 | 6 | 1.000 | 7 | 21 | 1 | 3 | 25 | 0.640 |
| ≥5 cm | 14 | 12 | 2 | 11 | 3 | 4 | 10 | 3 | 11 | |||||
| Histological classification | Adenocarcinoma | 40 | 33 | 7 | 1.000 | 31 | 9 | 1.000 | 10 | 30 | 1 | 4 | 36 | 0.558 |
| Mucinous adenocarcinoma | 2 | 2 | 0 | 2 | 0 | 1 | 1 | 1 | 1 | |||||
| Undifferentiated carcinoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
PCDH-γ-A12, protocadherin γ subfamily A12; SLC19A1, solute carrier family 19 A 1; CREB, cAMP responsive element binding protein; CYLD, cylindromatosis; M, methylated; U, unmethylated; TNM, tumor-node-metastasis; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.